Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Western New York Urology Associates Announces Dr. Ryan White's Designation as a UroLift® Center of Excellence

Posted on: 10 May 18
Western New York Urology Associates Announces Dr. Ryan White's Designation as a UroLift® Center of Excellence Designation Recognizes Dr. Ryan White's Commitment to Exemplary Care, Deep UroLift Experience

PR Newswire

JAMESTOWN, N.Y., May 10, 2018

JAMESTOWN, N.Y., May 10, 2018 /PRNewswire-PRWeb/ -- Western New York Urology Associates today announced that Dr. Ryan White has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. White has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH.

"The UroLift System is a breakthrough minimally invasive treatment that typically takes less than an hour and can offer multiple benefits for men with enlarged prostate – no cutting, heating, or removal of tissue, typically minimal downtime, no compromise of sexual function, and usually eliminates the need for continued medications," said Dr. White. "I am proud to be part of Western New York Urology Associates which now has three physicians designated as a Center of Excellence for The UroLift System."

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

About the UroLift System
NeoTract's FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at

About Western New York Urology Associates
Founded in 1996, Western New York Urology Associates has nine locations across the region, including sites in Cheektowaga, Cambria, Orchard Park, Jamestown, Dunkirk, Corfu, Hamburg, Derby and Springville. The practice has affiliation agreements with 23 hospitals and outpatient sites in the region and serves as a resident training site for the University at Buffalo School of Medicine & Biomedical Sciences.

Western New York Urology Associates, LLC.

Media Contact:
Amy Cramer
M: 650-391-3714



PR Newswire

Last updated on: 10/05/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.